India’s Advinus Signs On With Genzyme In Malaria Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of malaria drugs could qualify Genzyme for a priority review voucher under FDA’s tropical disease incentive.
You may also be interested in...
Summit Lends TB Program To Lilly Philanthropy
UK biotech keeps rights to sell new drugs in wealthier countries.
Summit Lends TB Program To Lilly Philanthropy
UK biotech keeps rights to sell new drugs in wealthier countries.
Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher
Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.